ImpediMed’s SOZO® Digital Health Platform is the only FDA-Cleared Bioimpedance Spectroscopy (BIS) technology that non-invasively measures fluid status and tissue composition in healthy and unhealthy patient populations. BIS enables clinicians to precisely monitor key health indicators, helping them to optimize real-time, personalized care.
Discover SOZO
Up to 58% of cancer patients are at risk for developing limb lymphedema.1 Treatment can cause changes in weight, muscle mass, bone health , and nutrition, impacting quality of life.
Closely monitor client response to wellness plans, including IV therapies, for sensitivities.
Rapid weight reduction with GLP-1s or other therapies can affect muscle mass by up to 20%.2,3
Heart failure (HF) affects ~64 million people world-wide.4 ~50% of patients with heart failure are overweight or obese.5
By measuring 256 frequencies in a single, rapid scan, BIS separates intra- and extracellular fluid for an accurate whole-body composition profile. Powered by BIS, the SOZO® Digital Health Platform delivers actionable data at the point of care, enabling informed treatment, recovery, and clinical decision-making with confidence.
Detecting lymphedema early, at a subclinical stage, can help prevent progression to a chronic condition.
Tracking fluid volumes and tissue composition can inform clinical decisions and motivate patient compliance for improved outcomes.
Understanding dynamic changes in fluid volume can provide a more complete picture of disease progression and treatment success.
From cancer survivorship, to heart health and wellness, the SOZO Digital Health Platform monitors patients for real-time changes to fluid status and tissue composition. With a cloud-connected platform, patients can be monitored and tracked across their treatment journey for comprehensive, personalized care.
